Dermata raises $3.5M gross in private placement; expects cash runway into Q2 2025

Dermata Therapeutics, Inc.

Gross proceeds $3.5M from 1,912,569 shares/pre-funded warrants + Series A & B warrants at $1.83/unit.
Net proceeds ~$3.0M after placement agent fees; H.C. Wainwright acted as exclusive agent.
Series A warrants (5.5 yr term) and Series B warrants (18 mo term) each exercisable at $1.58/share.
Including prior raises, total $7.8M gross since May 2024; operations funded into Q2 2025.
Proceeds for general corporate purposes including R&D, clinical trials, and licensing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.